{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:45:30Z","timestamp":1761101130255},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T00:00:00Z","timestamp":1385942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T00:00:00Z","timestamp":1385942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1038\/bmt.2013.186","type":"journal-article","created":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T11:35:39Z","timestamp":1385984139000},"page":"361-365","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)"],"prefix":"10.1038","volume":"49","author":[{"given":"P","family":"Chevallier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Milpied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Bilger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Soci\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-E","family":"Bulabois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Maury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Beguin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-O","family":"Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Guillerm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Daguindeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Raus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the SFGM-TC","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,2]]},"reference":[{"key":"BFbmt2013186_CR1","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMra052638","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA . Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813\u20131826.","journal-title":"N Engl J Med"},{"key":"BFbmt2013186_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/107327480200900205","volume":"9","author":"L Luznik","year":"2012","unstructured":"Luznik L, Fuchs EJ . Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2012; 9: 123\u2013137.","journal-title":"Cancer Control"},{"key":"BFbmt2013186_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1586\/ehm.10.21","volume":"3","author":"B Gyurkocza","year":"2010","unstructured":"Gyurkocza B, Rezvani A, Storb RF . Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol 2010; 3: 285\u2013299.","journal-title":"Expert Rev Hematol"},{"key":"BFbmt2013186_CR4","first-page":"w13696","volume":"142","author":"JR Passweg","year":"2012","unstructured":"Passweg JR, Halter J, Bucher C, Gerull S, Heim D, Rovo A et al. Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner. Swiss Med Wkly 2012; 142: w13696.","journal-title":"Swiss Med Wkly"},{"key":"BFbmt2013186_CR5","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2012.66","volume":"47","author":"JR Passweg","year":"2012","unstructured":"Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P et al. The EBMT activity survey: 1990\u20132010. Bone Marrow Transplant 2012; 47: 906\u2013923.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013186_CR6","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/leu.2010.200","volume":"24","author":"M Mohty","year":"2010","unstructured":"Mohty M, Labopin M, Bal\u00e8re ML, Socie G, Milpied N, Tabrizi R et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Soci\u00e9t\u00e9 Francaise de Greffe de Moelle et de Th\u00e9rapie Cellulaire. Leukemia 2010; 24: 1867\u20131874.","journal-title":"Leukemia"},{"key":"BFbmt2013186_CR7","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1182\/blood-2010-07-259358","volume":"116","author":"HJ Deeg","year":"2010","unstructured":"Deeg HJ, Sandmaier BM . Who is fit for allogeneic transplantation? Blood 2010; 116: 4762\u20134770.","journal-title":"Blood"},{"key":"BFbmt2013186_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/bmt.2009.141","volume":"45","author":"P Ljungman","year":"2010","unstructured":"Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219\u2013234.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013186_CR9","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","volume":"108","author":"C Schmid","year":"2006","unstructured":"Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity qconditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092\u20131099.","journal-title":"Blood"},{"key":"BFbmt2013186_CR10","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M, Klein JP, He Wensheng, Cahn JY, Cairo M, Camitta BM et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 3730\u20133738.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013186_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695\u2013706.","journal-title":"Stat Med"},{"key":"BFbmt2013186_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ . A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"BFbmt2013186_CR13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/sj.bmt.1705148","volume":"36","author":"M Yanada","year":"2005","unstructured":"Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005; 36: 867\u2013872.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013186_CR14","first-page":"513","volume":"91","author":"A Gratwohl","year":"2006","unstructured":"Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513\u2013521.","journal-title":"Haematologica"},{"key":"BFbmt2013186_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3324\/haematol.11960","volume":"93","author":"M Mohty","year":"2008","unstructured":"Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser A, Rambaldi A et al. Reduced-intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93: 303\u2013306.","journal-title":"Haematologica"},{"key":"BFbmt2013186_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/bmt.2008.258","volume":"42","author":"TH Terwey","year":"2008","unstructured":"Terwey TH, Massenkeil G, Tamm I, Hemmati PG, Neuburger S, Martus P et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant 2008; 42: 791\u2013798.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013186_CR17","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1182\/blood-2010-02-269571","volume":"116","author":"S Nishiwaki","year":"2010","unstructured":"Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H et al. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood 2010; 116: 4368\u20134375.","journal-title":"Blood"},{"key":"BFbmt2013186_CR18","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/leu.2011.13","volume":"25","author":"C Craddock","year":"2011","unstructured":"Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H et al. Fcators predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011; 25: 808\u2013813.","journal-title":"Leukemia"},{"key":"BFbmt2013186_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ajh.22273","volume":"87","author":"Q Bashir","year":"2012","unstructured":"Bashir Q, Khan H, Orlowski RZ, Amjad AL, Shah N, Parmar S et al. Predictors of prolongad survival alter allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 2012; 87: 272\u2013276.","journal-title":"Am J Hematol"},{"key":"BFbmt2013186_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/annonc\/mdf010","volume":"13","author":"H Bertz","year":"2002","unstructured":"Bertz H, Illerhaus G, Veelken H, Finke J . Allogeneic hematopoietic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 2002; 13: 135\u2013139.","journal-title":"Ann Oncol"},{"key":"BFbmt2013186_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3324\/haematol.11828","volume":"93","author":"P Anderlini","year":"2008","unstructured":"Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin\u2019s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93: 257\u2013264.","journal-title":"Haematologica"},{"key":"BFbmt2013186_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","volume":"14","author":"P Hari","year":"2008","unstructured":"Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236\u2013245.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013186_CR23","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","volume":"29","author":"RJ Van Kampen","year":"2011","unstructured":"Van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing aftera n autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342\u20131348.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013186_CR24","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1093\/annonc\/mds054","volume":"23","author":"S Le Gouill","year":"2012","unstructured":"Le Gouill S, Kroger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed\/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012; 23: 2695\u20132703.","journal-title":"Ann Oncol"},{"key":"BFbmt2013186_CR25","doi-asserted-by":"crossref","unstructured":"Detrait MY, Chevallier P, Sobh M, Guillaume T, Thomas X, Morisset S et al. Outcome of high-risk and refractory AML\/MDS patients receiving a FLAMSA sequential chemotherapy regimen followed by reduced-intensity conditioning (RIC) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). Blood (ASH Annual Meeting Abstracts) 2011; 118 Abstract 1957.","DOI":"10.1182\/blood.V118.21.1957.1957"},{"key":"BFbmt2013186_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.beha.2011.05.002","volume":"24","author":"A Shimoni","year":"2011","unstructured":"Shimoni A, Nagler A . Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still need. Best Pract Res Clin Haematol 2011; 24: 369\u2013379.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFbmt2013186_CR27","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1182\/blood-2012-02-406678","volume":"119","author":"M Mohty","year":"2012","unstructured":"Mohty M, Chevallier P . Azacitidine after allo-SCT: the good without the bad? Blood 2012; 119: 3199\u20133200.","journal-title":"Blood"},{"key":"BFbmt2013186_CR28","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","volume":"26","author":"P Chevallier","year":"2008","unstructured":"Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R et al. Long term disease free survival after the MIDAM (Mylotarg, intermediaite dose Ara-C, Mitoxantrone) regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 2008; 26: 5192\u20135197.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013186_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bjh.12299","volume":"161","author":"K Takahashi","year":"2013","unstructured":"Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S et al. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol 2013; 161: 659\u2013666.","journal-title":"Br J Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2013186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2013186","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2013186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T16:10:20Z","timestamp":1648051820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2013186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,2]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["BFbmt2013186"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2013.186","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2013,12,2]]},"assertion":[{"value":"6 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}